ESMO 2023 | Brain metastases and survival evaluation in the SECOMBIT trial

Georgina V. Long, PhD, MBBS, FRACP, FAHMS, The University of Sydney, North Sydney, Australia, discusses the Phase II SECOMBIT (NCT02631447) trial, which evaluated the best sequential approach for combo immunotherapy (I-O; ipilimumab plus nivolumab) and combo target therapy (T-T; encorafenib plus binimetinib) in patients with metastatic melanoma. Patients either received T-T until progression and then I-O (arm A), received I-O until progression and then T-T (arm B), or were treated with a ‘sandwich’ strategy (T-T, I-O, T-T; arm C). In a follow-up analysis, incidence of and timing to brain metastasis onset was investigated. Patients in arms B and C had a lower risk of developing brain metastasis compared to patients in arm A. Additionally, patients with high tumor mutational burden (TMB) had improved brain metastasis-free survival. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.